Table 4.
Estimated probability (%) of a treatment being the most effective in reducing the risk of a dichotomous outcome for high‐ and moderate‐quality studies
| Outcomes | Treatment | ||
|---|---|---|---|
| Metformin | Glyburide | Insulin | |
| LGA | 85.2 | 14.8 | 0.0 |
| Adverse maternal outcomes | 29.5 | 70.5 | 0.0 |
| Adverse neonatal outcomes | 91.8 | 8.1 | 0.0 |
| Excessive fetal growth | 55.7 | 44.3 | 0.0 |
| Hypertensive disorders of pregnancy | 81.3 | 17.4 | 1.3 |
| Neonatal metabolic disturbance | 93.2 | 6.8 | 0.0 |
| Serious neonatal conditions | 2.5 | 97.2 | 0.3 |
| Abnormal delivery | 0.3 | 97.8 | 1.9 |
| Macrosomia | 89.0 | 11.0 | 0.0 |
| Neonatal hypoglycemia | 91.0 | 0.9 | 0.0 |
| SGA | 7.3 | 82.8 | 9.9 |
| Cesarean section | 4.3 | 94.3 | 1.4 |
LGA, large for gestational age; SGA, small for gestational age.